TWI276622B - Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy -3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide - Google Patents

Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy -3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide Download PDF

Info

Publication number
TWI276622B
TWI276622B TW089106840A TW89106840A TWI276622B TW I276622 B TWI276622 B TW I276622B TW 089106840 A TW089106840 A TW 089106840A TW 89106840 A TW89106840 A TW 89106840A TW I276622 B TWI276622 B TW I276622B
Authority
TW
Taiwan
Prior art keywords
methoxy
ethyl
sodium salt
chloro
mixture
Prior art date
Application number
TW089106840A
Other languages
English (en)
Chinese (zh)
Inventor
Heinrich Christian Englert
Uwe Gerlach
Thomas Schnieder
Tobias Metzenthin
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of TWI276622B publication Critical patent/TWI276622B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW089106840A 1999-04-16 2000-05-10 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy -3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide TWI276622B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids

Publications (1)

Publication Number Publication Date
TWI276622B true TWI276622B (en) 2007-03-21

Family

ID=7904803

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089106840A TWI276622B (en) 1999-04-16 2000-05-10 Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy -3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide

Country Status (33)

Country Link
US (1) US6723751B1 (he)
EP (2) EP1637519B1 (he)
JP (1) JP4662640B2 (he)
KR (1) KR100700302B1 (he)
CN (1) CN1168712C (he)
AR (1) AR023479A1 (he)
AT (2) ATE414059T1 (he)
AU (1) AU773246B2 (he)
BR (1) BR0010658A (he)
CA (1) CA2370388C (he)
CZ (1) CZ302459B6 (he)
DE (3) DE19917233A1 (he)
DK (1) DK1173418T3 (he)
EE (1) EE04612B1 (he)
ES (1) ES2251996T3 (he)
HK (1) HK1046270B (he)
HR (1) HRP20010744B1 (he)
HU (1) HU229082B1 (he)
IL (2) IL145921A0 (he)
ME (1) MEP55708A (he)
MX (1) MXPA01010275A (he)
MY (1) MY122588A (he)
NO (1) NO327798B1 (he)
NZ (1) NZ514788A (he)
PL (1) PL203809B1 (he)
RS (1) RS50916B (he)
RU (1) RU2235089C2 (he)
SI (1) SI1173418T1 (he)
SK (1) SK287175B6 (he)
TR (2) TR200102993T2 (he)
TW (1) TWI276622B (he)
WO (1) WO2000063167A1 (he)
ZA (1) ZA200108400B (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289507A1 (en) * 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098069T3 (es) 1993-02-23 1997-04-16 Hoechst Ag Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y su utilizacion como agentes farmaceuticos.
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CZ301165B6 (cs) * 1998-09-10 2009-11-25 Sanofi - Aventis Deutschland GmbH Použití benzensulfonyl(thio)mocovin pro lécení a profylaxi dysfunkcí autonomní nervové soustavy a použití benzensulfonyl(thio)mocovin v kombinaci s beta-receptorovými blokátory

Also Published As

Publication number Publication date
DE60024431T2 (de) 2006-07-27
EE200100532A (et) 2002-12-16
NZ514788A (en) 2003-03-28
ATE414059T1 (de) 2008-11-15
EE04612B1 (et) 2006-04-17
KR100700302B1 (ko) 2007-03-29
NO327798B1 (no) 2009-09-28
YU72001A (sh) 2004-07-15
DE60024431D1 (en) 2006-01-05
JP2002542230A (ja) 2002-12-10
HRP20010744B1 (en) 2010-08-31
SK287175B6 (sk) 2010-02-08
ATE311364T1 (de) 2005-12-15
DK1173418T3 (da) 2006-04-10
CN1354744A (zh) 2002-06-19
MXPA01010275A (es) 2003-07-21
AR023479A1 (es) 2002-09-04
MEP55708A (en) 2011-05-10
CA2370388A1 (en) 2000-10-26
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
CA2370388C (en) 2009-10-13
EP1637519A1 (en) 2006-03-22
HRP20010744A2 (en) 2003-04-30
HK1046270A1 (en) 2003-01-03
ES2251996T3 (es) 2006-05-16
CZ20013672A3 (cs) 2002-01-16
HK1046270B (zh) 2005-03-11
NO20015014D0 (no) 2001-10-15
PL351245A1 (en) 2003-04-07
US6723751B1 (en) 2004-04-20
EP1173418B1 (en) 2005-11-30
CN1168712C (zh) 2004-09-29
EP1637519B1 (en) 2008-11-12
IL145921A0 (en) 2002-07-25
EP1173418A1 (en) 2002-01-23
WO2000063167A1 (en) 2000-10-26
AU773246B2 (en) 2004-05-20
DE60040811D1 (de) 2008-12-24
BR0010658A (pt) 2002-02-19
TR200501142T2 (tr) 2005-08-22
RS50916B (sr) 2010-08-31
CZ302459B6 (cs) 2011-06-01
MY122588A (en) 2006-04-29
ZA200108400B (en) 2003-04-30
IL145921A (he) 2006-07-05
HUP0200791A2 (hu) 2002-07-29
DE19917233A1 (de) 2000-10-19
HUP0200791A3 (en) 2005-04-28
JP4662640B2 (ja) 2011-03-30
AU4542800A (en) 2000-11-02
SI1173418T1 (sl) 2006-02-28
PL203809B1 (pl) 2009-11-30
NO20015014L (no) 2001-10-15
SK14582001A3 (sk) 2002-01-07
TR200102993T2 (tr) 2002-03-21
HU229082B1 (hu) 2013-07-29

Similar Documents

Publication Publication Date Title
TWI351949B (en) Cftr inhibitor compounds and uses thereof
US8076362B2 (en) Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
TW504505B (en) Substituted 1-oxo-1,2-dihydroisoquinolinoylguanidines and 1,1-dioxo-2H-1,2-benzothiazinoylguanidines, a process for their preparation, and a pharmaceutical composition containing them
TWI592407B (zh) 飢餓素ｏ－醯基轉移酶抑制劑
BR112016009488B1 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica
CA1258072A (en) 5-heteroarylimidazol-2-ones
JPH10508847A (ja) 酸化窒素合成酵素インヒビターとして有用なアミノテトラゾール誘導体
CN110418644A (zh) 包含jak抑制剂的药物组合物
JPH04308560A (ja) ベンズアミドおよびスルホンアミド低血糖剤
RU2468015C2 (ru) Полиморфные формы деферасирокса (icl670a)
TW397814B (en) Alkylbenzoylguanidine derivatives
TWI276622B (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy -3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide
US2704757A (en) 5-hydroxy-3, 4, 5, 6-tetrahydropyriminines
JP2001500149A (ja) 細胞増殖抑制性ヒドロキサム酸誘導体
JP2018520145A (ja) 効率的ｈｎｏドナーとしての炭素系脱離基を有するｎ−置換ヒドロキサム酸およびその使用
JP5092111B2 (ja) ブトキシアニリン誘導体
CA1065865A (en) Piperazinyluracil salt
JP7359460B2 (ja) 心不整脈および心不全の処置のための化合物
TW406074B (en) Heterocyclyloxybenzoylguanidines
JP2001519826A (ja) 金属プロテイナーゼ阻害剤
NO803911L (no) 3-acylamino-5-(pyridinyl)-2(1h)-pyridinoner og fremgangsmaate til fremstilling derav
CA3045887A1 (en) Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
SU936808A3 (ru) Способ получени производных декагидрохинолинола или их солей
KR20020040918A (ko) 나트륨-수소 교환체 타입 1 억제제 결정
JPH04305557A (ja) 置換アニリド

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees